Regulation Killed The DTC Ad

more+
less-

The FDA's proposed plan to implement its Section 503B pre-dissemination review has received pharma industry criticism, not only for being time and cost intensive, but also for potentially being unconstitutional. Will pharma advertisers seek social media shelter?

LOADING PDF: If there are any problems, click here to download the file.

Published In: Products Liability Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Sarah Lovequist, Litigation Management, Inc. | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »